(第4回泌尿器がん化学療法研究会学術集会)ホルモン非依存性前前立腺癌の治療

Abstract

Ninety-three patients with prostatic carcinoma were treated at Nara Medical University between 1969, April and 1980, March. The average age of patients was 70.6 years old and the age range was between 50 and 87. Ninety-one patients of whom had histologically proved adenocarcinoma, and two patients had proved transitional cell carcinoma of the prostate. Initial clinical stage was as follows: stage A 7 cases (7.5%), stage B 6 cases (6.5%), stage C 39 cases (41. 9 %) and stage D 41 cases (44.1 %). Histological grade was determined as follows: well differentiated type 20 cases (21.5%), moderately differentiated type 53 cases (57.0%), poorly differentiated type 9 cases (9.7%) and unidentified 9 cases (9.7%). Of ninety-three patients, 66 were treated with anti-androgen therapy, and 21 were treated with radiotherapy and/or chemotherapy because they had no response to initial hormonal manipulation, and remaining 6 cases underwent radical prostatectomy with adjuvant anti-androgen therapy. Relapse was seen in 20 patients: 15 were in the group of anti-androgen therapy, 4 were in the group of radiotherapy and/or chemotherapy following anti-androgen therapy and one was in the group of radical prostatectomy. The interval to relapse was 2.2 years on the average (range: 8 months to 6 years). Five years actuarial survival rates were 37.7% in the group of anti-androgen therapy, and 61.9% in the group of radiotherapy and/or chemotherapy, and the significant difference between these two groups was not seen. The 5 patients diagnosed as stage D adenocarcinoma of the prostate, 4 of whom had multiple bone metastasis and 2 had liver metastasis in addition to bone metastasis, showed favorable response to the administration of Cis-DDP.